Aqueous Sugar Film Coating System

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2018
Volume 42
Issue 2

Colorcon's Opadry SGR, Rapid Sugar Film Coating System, is an aqueous, high-gloss sugar film coating system for pharmaceutical products.

Colorcon’s Opadry SGR, Rapid Sugar Film Coating System, is an aqueous, high-gloss sugar film coating system for pharmaceutical products. The coating system delivers a streamlined application process by reducing coating time from days to hours and improving manufacturing safety through the elimination of organic solvents, according to the company. The system is color matched to meet marketing and brand needs and is suited for environments where less automated equipment is prevalent.

Colorcon

Download Issue PDF
Articles in this issue
Designing a Single-Use Biopharmaceutical Process
Designing a Single-Use Biopharmaceutical Process
Material Traceability in Continuous Pharmaceutical Tablet Manufacturing
Material Traceability in Continuous Pharmaceutical Tablet Manufacturing
Establishing Correlation Between Aerosol and Surface Microbial Populations
Establishing Correlation Between Aerosol and Surface Microbial Populations
Analyzing Content Uniformity
Analyzing Content Uniformity
Figure 1.jpg
The Power of Synchrotron X-Ray Powder Diffraction for the Characterization of Pharmaceuticals
Impurity Testing
Impurity Testing
PF701807_small-225-1.jpg
Tabletop Peristaltic Liquid-Filling Machine
Ross-Tumble-Blenders-(1,-5-and-7.5-cu.ft.)_225.jpg
Safety Light Curtain Feature on Tumble Blenders
10346-Colorcon-SGR-logo-and-Render-225.jpg
Aqueous Sugar Film Coating System
LogTag-Serie_USB_klein_225.jpg
USB Data Logger for Temperature-Sensitive Products
Navigating Data Integrity in the Modern Lab
Maintaining Lab Data Integrity
Maintaining Lab Data Integrity
Barriers to ATMP Drug Development
A New Business Model for Pharma?
Managing Risk in a Complex Excipient Supply Chain
Managing Risk in a Complex Excipient Supply Chain
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Beckman Coulter Life Sciences Launches Modular Spectral Flow Cytometry Module, First of Its Kind in Industry

Feliza Mirasol
March 28th 2025
Article

The CytoFLEX mosaic Spectral Detection Module offers up to 88 channels for detection.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations

Feliza Mirasol
March 27th 2025
Article

In the latest of a series of warning letters to India-based API manufacturers, FDA issued a warning letter to Aspen for deviations in CGMP in the production of APIs.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Novartis’ Steady Investments in Slovenia Result in New Viral Vector Manufacturing Facility and a Growing Work Force

Feliza Mirasol
March 27th 2025
Article

With a completed €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in R&D that has led to the growth of Slovenia’s workforce.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

CARBOGEN AMCIS Receives GMP Certification Following Successful ANSM Inspection

Patrick Lavery
March 26th 2025
Article

The company’s state-of-the-art sterile drug product manufacturing site in Saint-Beauzire, France, opened in February 2023.